Clinical Trial Update: An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab [Phase 3]

View source ↗

Summary

Phase 3 open-label trial evaluating the effectiveness and patient-reported outcomes of switching relapsing MS patients from dimethyl fumarate or fingolimod to o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)
• Kesimpta (ofatumumab)
• Tecfidera (dimethyl fumarate)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2025-11-12